Andere Sprachen Zentalis Pharmaceuticals, Inc.

Aktien

A2P209

US98943L1070

ZNTL

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:42:29 23.05.2024			% 5 Tage	% 1. Jan.
11,19 ^USD	-6,59 %		-5,52 %	-25,41 %

08.05.	ZENTALIS PHARMACEUTICALS, INC. : Stifel Nicolaus bekräftigt seine Kaufempfehlung	ZM
07.05.	Zentalis Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit	14.05.
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress	07.05.
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.05.
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	11.04.
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	11.04.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024	03.04.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024	02.04.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	02.04.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.04.
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	04.03.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.03.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	28.02.
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates	27.02.
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference	13.02.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.02.
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer	25.01.
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments	25.01.
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	25.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zentalis Pharmaceuticals, Inc.

Aktien

A2P209

US98943L1070

ZNTL

Andere Sprachen

Filter